Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe.
Read More
A new blood test that can detect more than 50 types of cancer in a single blood draw is now available in the United States with a prescription. Here are the details.
Read More
GRAIL, which manufactures cancer detection kits, will host a virtual open house as it seeks to hire nearly 400 people in the next four years.
Read More
GRAIL, the California-based biotech firm targeting cancer, is moving ahead quickly with plans to open a massive 200,000 square foot laboratory in RTP and is looking to hire “more than 100 workers” this year for a variety of positions.
Read More
San Diego-based Illumina, which founded GRAIL in 2016 and then spun it off as a standalone business, has reentered the picture. Here are the details.
Read More
The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.
Read More
GRAIL, a 5-year-old Menlo Park company whose mission is “to detect cancer early, when it can be cured,” has raised more than $2 billion in venture capital to support its development of a “liquid biopsy” blood test to detect more than 50 types of cancers in people, even before they develop symptoms. Now the company is expanding to North Carolina. Here’s a look at the firm.
Read More
GRAIL is a healthcare company whose mission is to detect cancer early. It is using the power of next-generation sequencing, population-scale clinical studies, and computer and data science to enhance the scientific understanding of cancer biology, and develop a multi-cancer early detection blood test
Read More
